CX1763
CX1763 is an AMPAR allosteric modulator. CX1763 allosterically potentiates glutamate-evoked currents, accelerates channel opening, and increases the surface levels of AMPAR containing Glur2 (R). CX1763 enhances synaptic transmission in the rat hippocampus. CX1763 improves attention in rats and attenuates amphetamine-induced hyperactivity in mice. CX1763 can be used in studies related to attention deficit hyperactivity disorder and opioid-induced respiratory depression.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1086378-73-5
- Fòrmula: C14H17N3O3
- Peso molecular:275.30
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas iGluR
More
Actividad biológica
|
AMPA Receptor |
CX1763 (100 μM) acts as a low-impact AMPA receptor positive allosteric modulator in rat brain membranes and neurons, increasing [3H]AMPA binding and peak glutamate-induced currents without intrinsic agonism up to 100 μM, and upregulating calcium-impermeable GluR2(R)-containing receptors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CX1763 (1-5 mg/kg; i.p.; single administration) improves specific attention parameters (shortens response latency, reduces premature responses) in the 5CSRTT ADHD rat model at the 5 mg/kg i.p. dose, while increasing omission errors without altering the correct response rate[1].
CX1763 (1-18 mg/kg; i.p.; single administration) dose-dependently reduces amphetamine-induced hyperactivity in mice, with an AD50 of 2 mg/kg, and completely reverses this symptom at 18 mg/kg via intraperitoneal injection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Long-Evans (male, 250-350 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose
-
Result:Significantly potentiated hippocampal fEPSP amplitude by ~20% at 15 minutes post-dose.
Peaked at ~15 minutes post-dose.
Declined to baseline by 100-120 minutes post-dose.
-
Animal Model:hooded Wistar (male, 250-310 g, 5-Choice Serial Reaction Time Task trained)[1]
-
Dosage:1 mg/kg; 5 mg/kg
-
Administration:i.p.; single dose
-
Result:Did not significantly alter 5CSRTT parameters at 1 mg/kg.
Significantly decreased correct response latency at 5 mg/kg.
Significantly decreased the percentage of premature responses at 5 mg/kg.
Significantly increased omission errors at 5 mg/kg.
Did not significantly improve the percentage of correct responses at 5 mg/kg.
-
Animal Model:CD1[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg; 18 mg/kg
-
Administration:i.p.; single dose
-
Result:Dose-dependently reduced amphetamine-induced hyperactivity, with an AD50 of 2 mg/kg.
Significantly reduced hyperactivity at doses of 3-18 mg/kg.
Completely reversed amphetamine-induced hyperactivity to baseline levels at 18 mg/kg.
Chemical Information
-
No. CAS 1086378-73-5
-
Peso molecular 275.30
-
Fòrmula C14H17N3O3
-
SMILES
CN([C@H]1CC[C@@H](CC1)O)C(C2=CC3=NON=C3C=C2)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CX1763 Related Classifications
HY-182631 Related Classifications
Powered by Bioz